Subscribe or Manage Preferences

Value Propositions

In an effort to evaluate the cost-effectiveness and utility of using integrated care interventions and participatory workplace interventions to increase productivity among workers with RA, Cindy Noben, PhD, Faculty of Health, Medicine and Life Sciences, Caphri School for Public Health and Primary Care, Maastricht University, the Netherlands, and colleagues conducted a 12-month follow-up at specialized rheumatology treatment centers, in addition to a randomized controlled trial that was carried out between 2011 and 2013.
  • Application and Population Management System Undergoing Testing for the Management of Flares in Patients with Rheumatoid Arthritis
  • Humana Adds MDLIVE Telemedicine Technology Benefit to Select Medicare Advantage Plans
  • Applications Being Developed to Provide Patients with Timely Drug Cost Information
  • Routine Monitoring of Drug Levels and Antidrug Antibodies Benefits Cost, Improves Treatment Decision-Making
  • Switching Between Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
  • Tofacitinib Treatment Demonstrates Cost Benefits in Patients with Rheumatoid Arthritis
  • Portable Device Offers Easier, Cost-Effective Approach to Gout Diagnosis
  • Efficacy and Safety Maintained for Up to 5 Years with Tocilizumab Therapy
  • First Ever Treatment Guidelines for Managing Rheumatologic Manifestations of Sjögren’s Syndrome
  • Short-Term Use of Soft Lateral Wedge Arch Support Significantly Reduces Pain in Patients with Knee Osteoarthritis
  • Tocilizumab Effective, Highly Retentive in Patients with Rheumatoid Arthritis
  • Cardiovascular Screening Cost-Effective in Patients with Rheumatoid Arthritis
  • Decernotinib, DMARD Combination Reduces Symptoms, Signs of Rheumatoid Arthritis
  • Efficacy of Etanercept, Methotrexate Combination Independent of Methotrexate Dosage
  • Rapid Access Rheumatology Consultations Feasible, Beneficial
  • Etanercept plus MTX More Cost-Effective than Monotherapy in Patients with Severe JIA
  • Higher Costs Linked to Lower DMARD Initiations, Refills in MAPD Members with RA
  • Higher Social Support Associated with Less Depression in Older Patients with RA
  • Bariatric Surgery Before Knee Arthroplasty
  • Adalimumab Proves Most Cost-Effective?
  • Online Reviews from Patients
  • Selective Uric Acid Reabsorption Inhibitor Approved
  • Challenging Step Therapy
Sanofi US has announced that Winthrop US, its generic division, will begin providing an authorized generic version of Arava tablets indicated for the treatment of active rheumatoid arthritis in adults.
As the healthcare system in the United States moves slowly toward a value-based strategy, a recent online article noted that value-based care can lower costs and is certainly beneficial for insurers, including Medicare, but asked, “...does it bring benefits to physicians or patients?”
After reporting on the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids in osteoarthritis at the 2015 Osteoarthritis Research Society International World Congress in Seattle, WA, Jeffrey Katz, MD, and colleagues have published online their findings on the cost-effectiveness of NSAIDs in the treatment of older patients with OA and multiple comorbidities.
Page 1 of 9
Results 1 - 10 of 86
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology